ArticleEvidence-based complementary and alternative medicine : eCAM2018
A Computational Approach Using Bioinformatics to Screening Drug Targets for
Article in Evidence-based complementary and alternative medicine : eCAM, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- Hit-to-Lead Studies of Pyrazinylpiperazines against Visceral Leishmaniasis: Pharmacokinetic Profile andACS pharmacology & translational science · 2025Article
- Target fishing: from "needle in haystack" to "precise guidance"--new technology, new strategy and new opportunity.Frontiers in pharmacology · 2025Review
- In Vivo Glycemic Response of Fruit-Based Mango (Foods (Basel, Switzerland) · 2024Article
- Evaluation of the merit of ethanolic extract ofF1000Research · 2023Article
- Identification of protein profile in metacyclic and amastigote-like stages of Leishmania tropica: a proteomic approach.AMB Express · 2022Article
- The miR-145-5p/CD36 pathway mediates PCB2-induced apoptosis in MCF-7 cells.Genes & genomics · 2021Article
- SystematicFrontiers in chemistry · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe development of new therapeutic strategies to treat patients for leishmaniasis has become a priority. The antileishmanial activity of the strychnobiflavone flavonoid was recently demonstrated against METHODS AND
resultsIn this study, a computational approach using bioinformatics was performed to screen biological targets of strychnobiflavone in
conclusionIn this context, this study provides the basis for understanding the mechanism of action of strychnobiflavone in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.